论文部分内容阅读
健康志愿者１０名，随机交叉口服硫酸吗啡控释片（ＣＲＭＳ）３０ｍｇ（３０ｍｇ×１）和硫酸吗啡普通片（ＩＲＭＳ）２０ｍｇ（１０ｍｇ×２），分别于服药前后各时点取静脉血，用ＧＣＭＳ测定血浆中吗啡含量。以药代软件程序处理，分别求得ＣＲＭＳ和ＩＲＭＳ的Ｃｍａｘ为１９．３８±３．８０和２１．２７±６．２１ｎｇ／ｍｌ；ｔｍａｘ为２．３６±０．３７ｈ和０．５５±０．１６ｈ；ｔ１／２β为３．５３±０．８７ｈ和３．０３±０．７４ｈ，曲线下面积ＡＵＣ为１４５．１５±１７．６５和９３．０８±１６．６５ｎｇ·ｈ／ｍｌ。癌症病人多次口服硫酸吗啡至稳态，ＣＲＭＳ和ＩＲＭＳ的峰浓度分别为２７．４３±０．３３ｎｇ／ｍｌ，２２．６８±０．１６ｎｇ／ｍｌ；谷浓度分别为１９．４５±１．４４ｎｇ／ｍｌ；１８．１４±０．４９ｎｇ／ｍｌ。
Ten healthy volunteers were randomized to receive oral morphine sulfate (30mg x 1) and morphine sulfate 20mg (10mg x 2) randomized to receive venous blood at various time points GC MS determination of plasma morphine content. The pharmacokinetic program was used to calculate the Cmax of CRMS and IRMS respectively, 19.38 ± 3.80 and 21.27 ± 6.21ng / ml; tmax was 2.36 ± 0.37h and 0.55 ± 0 respectively. 16h; t1 / 2β was 3.53 ± 0.87h and 3.03 ± 0.74h, the area under the curve AUC was 145.15 ± 17.65 and 93.08 ± 16.65ng · h / ml respectively. Cancer patients repeatedly oral morphine sulfate steady state, CRMS and IRMS peak concentrations were 27.43 ± 0.33ng / ml, 22.68 ± 0.16ng / ml; trough concentrations were 19.45 ± 1.44ng / Ml; 18.14 ± 0.49 ng / ml.